Evidence map›Paper›PMID 42067559›Full record

ArticleBlood cancer journal2026

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients.

Ross S Firestone, Anish K Simhal, Theresia Akhlaghi, Jung Hun Oh, Devin McAvoy, Kylee H Maclachlan, Juan-Jose Garces, Sham Mailankody, Hani Hassoun, Urvi A Shah and 10 more

Abstract readLetter
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ross S Firestone *Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. firestor@mskcc.org.ORCID http://orcid.org/0000-0002-2945-9320
Anish K Simhal *Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Theresia AkhlaghiMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-8826-4646
Jung Hun OhDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Devin McAvoyImmune discovery and modeling service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kylee H MaclachlanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7873-4854
Juan-Jose GarcesMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sham MailankodyMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2815-9561
Hani HassounMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2036-1749
Urvi A ShahMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8419-1091
Neha KordeMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5538-4318
Carlyn R TanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7922-2594
Sridevi RajeeveMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3458-824X
Hamza HashmiMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4129-5867
Alexander M LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9321-702X
Kinga HosszuImmune discovery and modeling service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-1190-1491
Francesco MauraMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5017-1620
Joseph O DeasyDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Saad Z UsmaniMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org.ORCID http://orcid.org/0000-0002-5484-8731
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hultcram@mskcc.org.ORCID http://orcid.org/0000-0002-9045-6495

Funding

Conquer Cancer Foundation (Conquer Cancer Foundation of the American Society of Clinical Oncology) N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42067559
PMCPMC13134959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.